Skip Navigation LinksHome > January 2014 - Volume 22 - Issue 1 > Purpuric Drug Eruption Secondary to Fidaxomicin
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e318281d8d7
Case Reports

Purpuric Drug Eruption Secondary to Fidaxomicin

Mucci, Tania MD,; Davis-Lorton, Mark MD

Collapse Box


Abstract: Fidaxomicin is a recently Food and Drug Administration–approved oral medication for the treatment of Clostridium difficile infection. This medication is typically reserved for patients who have failed therapy with oral metronidazole. Here we present a case of a 79-year-old man with recurrent C. difficile infection who developed pitting lower extremity edema and a confluent, purpuric drug eruption 3 days into treatment with fidaxomicin. The rash improved completely with cessation of the medication. To our knowledge, this is the first report of a purpuric drug eruption secondary to fidaxomicin.

© 2014 Wolters Kluwer Health, Inc. All rights reserved.

Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.